S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
66,000% upside on tiny biotech? (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Oil tanker breaks down in Egypt's Suez Canal, disrupting traffic in the global waterway
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
66,000% upside on tiny biotech? (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Oil tanker breaks down in Egypt's Suez Canal, disrupting traffic in the global waterway
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
66,000% upside on tiny biotech? (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Oil tanker breaks down in Egypt's Suez Canal, disrupting traffic in the global waterway
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
66,000% upside on tiny biotech? (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Oil tanker breaks down in Egypt's Suez Canal, disrupting traffic in the global waterway
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
Lowest-Rated StocksLowest-Rated
NASDAQ:GMAB

Genmab A/S (GMAB) Stock Forecast, Price & News

$39.57
+0.24 (+0.61%)
(As of 06/2/2023 ET)
Compare
Today's Range
$39.01
▼
$39.57
50-Day Range
$37.12
▼
$42.94
52-Week Range
$26.19
▼
$47.50
Volume
258,086 shs
Average Volume
347,047 shs
Market Capitalization
$26.11 billion
P/E Ratio
35.65
Dividend Yield
N/A
Price Target
$39.15
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Genmab A/S MarketRank™ Forecast

Analyst Rating
Hold
2.08 Rating Score
Upside/​Downside
1,498.7% Upside
$632.62 Price Target
Short Interest
Healthy
0.51% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.62mentions of Genmab A/S in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
30.30%
From $0.99 to $1.29 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.33 out of 5 stars

Medical Sector

178th out of 983 stocks

Pharmaceutical Preparations Industry

77th out of 486 stocks

See Top Rated MarketRank™ Stocks Here

GMAB stock logo

About Genmab A/S (NASDAQ:GMAB) Stock

Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline include daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998 and is headquartered in Copenhagen, Denmark.

Receive GMAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genmab A/S and its competitors with MarketBeat's FREE daily newsletter.

GMAB Stock News Headlines

June 2, 2023 | americanbankingnews.com
Genmab A/S (NASDAQ:GMAB) Research Coverage Started at UBS Group
May 29, 2023 | markets.businessinsider.com
SVB Securities Sticks to Its Hold Rating for Genmab (GMAB)
June 4, 2023 | Behind the Markets (Ad)
How A.I. Could Make Most 21st Century Diseases EXTINCT
On December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...
May 28, 2023 | americanbankingnews.com
Genmab A/S (NASDAQ:GMAB) Receives $752.95 Consensus PT from Analysts
May 27, 2023 | americanbankingnews.com
Genmab A/S (NASDAQ:GMAB) to Post FY2024 Earnings of $0.83 Per Share, HC Wainwright Forecasts
May 26, 2023 | americanbankingnews.com
Genmab A/S to Post Q2 2024 Earnings of $0.25 Per Share, HC Wainwright Forecasts (NASDAQ:GMAB)
May 26, 2023 | americanbankingnews.com
Genmab A/S to Post FY2023 Earnings of $1.01 Per Share, William Blair Forecasts (NASDAQ:GMAB)
May 25, 2023 | finance.yahoo.com
Genmab Announces Multiple Abstracts to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) Congress
June 4, 2023 | Legacy Research (Affiliate) (Ad)
“Amazon Loophole” could hand you $28,544 in “royalty” payouts
Thanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.
May 24, 2023 | americanbankingnews.com
HC Wainwright Boosts Genmab A/S (NASDAQ:GMAB) Price Target to $51.00
May 22, 2023 | finance.yahoo.com
AbbVie (ABBV) Gets FDA Nod for Lymphoma Drug Epcoritamab
May 20, 2023 | americanbankingnews.com
Q2 2023 EPS Estimates for Genmab A/S Lifted by HC Wainwright (NASDAQ:GMAB)
May 19, 2023 | msn.com
AbbVie, Genmab granted FDA nod for lymphoma therapy
May 19, 2023 | msn.com
FDA Approves AbbVie/Genmab's Cancer Drug As First Bispecific Antibody For Type Of Lymphoma In Adult Patients
May 19, 2023 | reuters.com
US FDA approves Genmab-AbbVie's blood cancer therapy
May 16, 2023 | americanbankingnews.com
Genmab A/S (NASDAQ:GMAB) PT Raised to $47.00 at HC Wainwright
May 16, 2023 | americanbankingnews.com
Q2 2023 Earnings Forecast for Genmab A/S Issued By SVB Leerink (NASDAQ:GMAB)
May 16, 2023 | americanbankingnews.com
Genmab A/S Forecasted to Earn Q2 2023 Earnings of $0.28 Per Share (NASDAQ:GMAB)
May 14, 2023 | americanbankingnews.com
Q3 2023 EPS Estimates for Genmab A/S (NASDAQ:GMAB) Increased by Analyst
May 13, 2023 | americanbankingnews.com
Genmab A/S (NASDAQ:GMAB) Shares Gap Up to $40.35
May 12, 2023 | msn.com
8 Best Biotech Stocks to Buy in 2023
May 12, 2023 | americanbankingnews.com
Genmab A/S (NASDAQ:GMAB) Receives New Coverage from Analysts at Morgan Stanley
May 11, 2023 | markets.businessinsider.com
Analysts Have Conflicting Sentiments on These Healthcare Companies: Genmab (GMAB) and Innate Pharma (IPHA)
May 10, 2023 | msn.com
Genmab A/S GAAP EPS of DKK3.43 beats by DKK3.27, revenue of DKK2.85B
May 8, 2023 | msn.com
How To Attend Genmab Q1 2023 Earnings Conference Call
May 5, 2023 | americanbankingnews.com
Genmab A/S (NASDAQ:GMAB) Receives Consensus Recommendation of "Hold" from Analysts
April 27, 2023 | msn.com
Price Over Earnings Overview: Genmab
See More Headlines

GMAB Price History

GMAB Company Calendar

Last Earnings
11/10/2021
Today
6/03/2023
Next Earnings (Estimated)
8/09/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GMAB
CUSIP
N/A
CIK
1434265
Web
www.genmab.com
Phone
(457) 020-2728
Fax
N/A
Employees
1,660
Year Founded
1999

Price Target and Rating

Average Stock Price Forecast
$632.62
High Stock Price Forecast
$3,600.00
Low Stock Price Forecast
$31.00
Forecasted Upside/Downside
-1.1%
Consensus Rating
Hold
Rating Score (0-4)
2.08
Research Coverage
12 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$1.11
Trailing P/E Ratio
35.65
Forward P/E Ratio
39.97
P/E Growth
1.95
Net Income
$781.91 million
Net Margins
34.34%
Pretax Margin
44.26%
Return on Equity
19.67%
Return on Assets
17.52%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
14.44
Quick Ratio
14.44

Sales & Book Value

Annual Sales
$2.07 billion
Price / Sales
12.63
Cash Flow
$1.27 per share
Price / Cash Flow
31.13
Book Value
$5.94 per share
Price / Book
6.66

Miscellaneous

Outstanding Shares
659,860,000
Free Float
649,697,000
Market Cap
$26.11 billion
Optionable
Not Optionable
Beta
0.96

Social Links


Key Executives

  • Jan G. J. van de Winkel
    President & Chief Executive Officer
  • Anthony Mancini
    Chief Operating Officer & Executive Vice President
  • Anthony Pagano
    Chief Financial Officer & Executive Vice President
  • Tahamtan Ahmadi
    Chief Medical Officer & Executive Vice President
  • Martine J. van Vugt
    Chief Strategy Officer & Executive Vice President

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













GMAB Stock - Frequently Asked Questions

Should I buy or sell Genmab A/S stock right now?

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Genmab A/S in the last year. There are currently 2 sell ratings, 7 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" GMAB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GMAB, but not buy additional shares or sell existing shares.
View GMAB analyst ratings or view top-rated stocks.

What is Genmab A/S's stock price forecast for 2023?

12 Wall Street analysts have issued 12 month price targets for Genmab A/S's shares. Their GMAB share price forecasts range from $31.00 to $3,600.00. On average, they expect the company's stock price to reach $632.62 in the next twelve months. This suggests a possible upside of 1,498.7% from the stock's current price.
View analysts price targets for GMAB or view top-rated stocks among Wall Street analysts.

How have GMAB shares performed in 2023?

Genmab A/S's stock was trading at $42.38 on January 1st, 2023. Since then, GMAB stock has decreased by 6.6% and is now trading at $39.57.
View the best growth stocks for 2023 here.

When is Genmab A/S's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023.
View our GMAB earnings forecast.

How were Genmab A/S's earnings last quarter?

Genmab A/S (NASDAQ:GMAB) released its quarterly earnings results on Wednesday, November, 10th. The company reported $0.21 EPS for the quarter, beating analysts' consensus estimates of $0.11 by $0.10. The company earned $366.25 million during the quarter, compared to analysts' expectations of $341.46 million. Genmab A/S had a net margin of 34.34% and a trailing twelve-month return on equity of 19.67%. During the same quarter last year, the business posted $0.13 earnings per share.

What ETFs hold Genmab A/S's stock?

ETFs with the largest weight of Genmab A/S (NASDAQ:GMAB) stock in their portfolio include Loncar Cancer Immunotherapy ETF (CNCR), First Trust NYSE Arca Biotechnology Index Fund (FBT), iShares Biotechnology ETF (IBB), Goldman Sachs Future Health Care Equity ETF (GDOC), WisdomTree BioRevolution Fund (WDNA), BlackRock Future Health ETF (BMED), Pacer Trendpilot International ETF (PTIN) and Invesco Nasdaq Biotechnology ETF (IBBQ).

What guidance has Genmab A/S issued on next quarter's earnings?

Genmab A/S updated its FY 2023 earnings guidance on Friday, May, 26th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.94 billion-$2.13 billion, compared to the consensus revenue estimate of $2.31 billion.

What other stocks do shareholders of Genmab A/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Genmab A/S investors own include NVIDIA (NVDA), Alibaba Group (BABA), Johnson & Johnson (JNJ), CVS Health (CVS), Home Depot (HD), Intel (INTC), Pfizer (PFE), PayPal (PYPL), Verizon Communications (VZ) and Cisco Systems (CSCO).

When did Genmab A/S IPO?

(GMAB) raised $503 million in an initial public offering (IPO) on Thursday, July 18th 2019. The company issued 27,800,000 shares at a price of $18.11 per share. BofA Merrill Lynch, Morgan Stanley and Jefferies served as the underwriters for the IPO and Guggenheim Securities and RBC Capital Markets were co-managers.

What is Genmab A/S's stock symbol?

Genmab A/S trades on the NASDAQ under the ticker symbol "GMAB."

Who are Genmab A/S's major shareholders?

Genmab A/S's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (0.80%), Macquarie Group Ltd. (0.53%), Wellington Management Group LLP (0.37%), 1832 Asset Management L.P. (0.34%), First Trust Advisors LP (0.19%) and Envestnet Asset Management Inc. (0.17%).

How do I buy shares of Genmab A/S?

Shares of GMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Genmab A/S's stock price today?

One share of GMAB stock can currently be purchased for approximately $39.57.

How much money does Genmab A/S make?

Genmab A/S (NASDAQ:GMAB) has a market capitalization of $26.11 billion and generates $2.07 billion in revenue each year. The company earns $781.91 million in net income (profit) each year or $1.11 on an earnings per share basis.

How many employees does Genmab A/S have?

The company employs 1,660 workers across the globe.

How can I contact Genmab A/S?

Genmab A/S's mailing address is Kalvebod Brygge 43, Copenhagen G7, 1560. The official website for the company is www.genmab.com. The company can be reached via phone at (457) 020-2728 or via email at acn@genmab.com.

This page (NASDAQ:GMAB) was last updated on 6/4/2023 by MarketBeat.com Staff

My Account -